Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Merck expands partnership with Zymeworks for multispecific antibodies

New licence agreement builds on existing collaboration

- PMLiVE

Novartis reveals full phase 3 results for Enerzair Breezhaler

Asthma treatment received EU approval earlier this week

- PMLiVE

Novartis forms coronavirus alliance with life sciences companies

Partnership will accelerate research with aid of Gates Foundation

- PMLiVE

Novartis says data backs safety of on-hold intrathecal Zolgensma

Data also demonstrated 'remarkable' efficacy in SMA type 2

Novartis day

Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

- PMLiVE

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

New-generation shot could protect franchise from rival Merck & Co

- PMLiVE

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

- PMLiVE

Keytruda hits primary endpoint in confirmatory lymphoma trial

Interim analysis demonstrates improvement in progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links